Advertisement
Research Article| Volume 44, ISSUE 3, P159-169, November 1991

Two year Cottbus reinfarction study with 30 mg aspirin per day

  • W. Hoffman
    Correspondence
    Address for correspondence: OMR Doc. Dr. sc. med. W. Hoffmann, Angiologische Abteilung der Medizinischen Poliklinik, Bezirkskrankenhaus Cottbus, Box 345, 0-7500 Cottbus, Germany.
    Affiliations
    District Hospital, 0-7500 Cottbus, Germany

    Department of Pharmacology and Toxicology, Martin Luther-University Halle-Wittenberg, 0-4010 Halle/Saale, Germany (Reprint requests to WF)
    Search for articles by this author
  • W. Förster
    Affiliations
    District Hospital, 0-7500 Cottbus, Germany

    Department of Pharmacology and Toxicology, Martin Luther-University Halle-Wittenberg, 0-4010 Halle/Saale, Germany (Reprint requests to WF)
    Search for articles by this author
DOI:https://doi.org/10.1016/0952-3278(91)90051-6
Two year Cottbus reinfarction study with 30 mg aspirin per day
Previous ArticleInfluence of aminophylline and ketotifen in comparison to the lipoxygenase inhibitors NDGA and esculetin and the PAF antagonists WEB 2107 and BN 52021 on Endothelin-1 induced vaso- and bronchoconstriction
Next ArticleCanine parainfluenza type 2 and Bordetella bronchiseptica infection produces increased bronchoalveolar lavage thromboxane concentrations in beagle puppies
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      All 701 heart infarction patients admitted to 15 hospitals in the district of Cottbus between 1981 and 1983 were randomly administered 30, 60 or 1000 mg aspirin daily according to the territorial affiliation of their local hospitals. The physical and drug therapy during the 2 years follow-up was highly standadized; deviations — as far as they occurred — were documented. Lower all-cause mortality was statistically demonstrated in patients over 60 and a lower fatal reinfarction rate in patients over 50 as well as in men. Deaths and fatal reinfarctions were significantly lower among patients with a history of angina pectoris, marked ST-depression, with an infarction location except for the posterior wall and among hypercholesterolemic patients. The preventive effect of 60 mg aspirin daily was less than that of 30 mg in comparison to the 1000 mg group. Side effects were seen in 4 and 8% (first and second year), respectively, of the patients administered 30 mg aspirin as opposed to 22 and 17% in patients allocated 1000 mg.
      We conclude that the optimum dose of aspirin for preventing reinfarctions could be as low as 30 mg daily.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Prostaglandins, Leukotrienes and Essential Fatty Acids
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. Br. Med. J. 1988; 296: 320-331
      2. Lancet. 1988; 2: 349-360
        • Meister W.
        • v. Schacky C.
        • Weber M.
        • Lorenz R.
        • Kotzur J.
        • Reichart B.
        • Theisen K.
        • Weber P.C.
        Low-dose acetylsalicylic acid (100 mg/day) after aortocoronary bypass surgery: a placebo-controlled trial.
        Br. J. clin. Pharmacol. 1984; 17: 703-711
        • De Catherina R.
        • Giannessi D.
        • Bernini W.
        • Gazzetti P.
        • Michelassi C.
        • L'Abbate A.
        • Donato L.
        • Patrignani P.
        • Filabozzi P.
        • Patrono C.
        Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function.
        Eur. Heart J. 1985; 6: 409-417
        • De Catherina R.
        • Giannessi D.
        • Bernini W.
        • Boem A.
        • Patrignani P.
        • Filabozzi P.
        • Patrono C.
        Aspirin after acute myocardial infarction: a systematic approach to compare the hemostatic effects of three different doses.
        in: 2nd ed. Adv. in Prostaglandin, Thromboxane, and Leukotriene Research. Vol. 13. Raven Press, New York1985: 267-270 (G. C. Neri Serneri, et al.)
        • Kretschmer V.
        • Schikor B.
        • Söhngen D.
        • Dietrich G.
        In vitro bleeding test — a simple method for the detection of aspirin effects on platelet function.
        Thromb. Res. 1989; 56: 593-602
        • Küster L.J.
        • Frölich J.C.
        Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man.
        Prostaglandins. 1986; 32: 415-423
        • McLeod L.J.
        • Roberts M.S.
        • Cossum P.A.
        • Vial J.H.
        The effects of different doses of some acetylsalicylic acid formulations on platelet function and bleeding times in healthy subjects.
        Scand. J. Haematol. 1986; 36: 379-384
        • Nuotto E.
        • Gordin A.
        • Paasonen M.K.
        • Metsä-Ketelä T.
        • Lammin-sivu U.
        Effects of acetylsalicylic acid on plasma thromboxane B2 and platelet aggregation in man.
        Eur. J. clin. Pharmacol. 1983; 25: 313-317
        • FitzGerald G.A.
        • Oates J.A.
        • Hawiger J.
        • Maas R.L.
        • Jackson Roberts II, L.
        • Lawson J.A.
        • Brash A.R.
        Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man.
        J. clin Invest. 1983; 71: 676-688
        • Jakubowski J.A.
        • Stampfer M.J.
        • Vaillancourt R.
        • Deykin D.
        Cumulative antiplatelet effect of low-dose enteric coated aspirin.
        Br. J. Haematol. 1985; 60: 635-642
        • Numano J.
        • Maruyama Y.
        • Koyama T.
        • Numano J.
        Antiaggregative aspirin dosage at the affected vessel wall.
        Angiology. 1986; 37: 695-701
        • Weksler B.B.
        • Pett S.B.
        • Alonso D.
        • Richter R.C.
        • Stelzer P.
        • Subramanian V.
        • Karen Tack-Goldman B.S.
        • Gay W.A.
        Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients.
        New Engl. J. 1983; 308: 800-805
        • Weksler B.B.
        • Karen Tack-Goldman B.A.
        • Subramanian V.A.
        • Gay W.A.
        Cumulative inhibitory effect of low-dose aspirin on vascular prostacyclin and platelet thromboxane production in patients with atherosclerotic.
        Circulation. 1985; 71: 332-340
        • Gerrard J.M.
        • Taback S.
        • Singhroy S.
        • Docherty J.C.
        • Kostolansky I.
        • McNicol A.
        • Kobrinsky N.L.
        • McKenzie J.K.
        • Rowe R.
        In vivo measurement of thromboxone B2 and 6-keto-prostaglandin F1a in humans in response to a standardized vascular injury and the influence of aspirin.
        Circulation. 1989; 79: 29-38
        • Preston F.E.
        • Whipps S.
        • Jackson C.A.
        • French A.J.
        • Wyld P.J.
        • Stoddard C.J.
        Inhibition of prostacyclin and platelet thromboxane A2 after low-dose aspirin.
        New. Engl. J. 1981; 304: 76-79
        • Preston F.E.
        • Greaves M.
        • Jackson C.A.
        Cumulative inhibitory effect of daily 40 mg aspirin on prostacyclin synthesis.
        Lancet. 1981; 1: 1211-1212
        • Kyrle P.A.
        • Eichler H.G.
        • Jäger U.
        • Lechner K.
        Inhibition of prostacyclin and thromboxane A2 generation by low-dose aspirin at the site of plug formation in man in vivo.
        Circulation. 1987; 75: 1025-1029
        • Patrono C.
        • Ciabattoni G.
        • Pinca E.
        • Pugliese F.
        • Gastrucci G.
        • DeSalvo A.
        • Satta M.A.
        • Peskar B.A.
        Low-dose aspirin and inhibition of thromboxane B2 in healthy subjects.
        Thromb. Res. 1980; 17: 317-327
        • Hoffmann W
        Zweijahresstudie an den Herzinfarkt-Patienten des Bezirkes Cottbus mit 30, 60 und 1000 mg Acetylsalicylsäure pro Tag.
        in: Dissertation. 2nd ed. Akademie für Ärztliche Fortbildung, Berlin1987
        • Hoffmann W.
        • Förster W.
        Two years follow-up Cottbus Reinfarction Study with 30 and 60 mg acetylsalicylic acid.
        in: 2nd ed. Prostaglandin in Clin. Research. Vol. 242. Alan R Liss, New York1987: 393-397
        • Förster W.
        • Hoffmann W.
        Two years follow-up study on the use of acetylsalicylic acid to prevent reinfarction and cardiac death in patients from the Cottbus region.
        in: Papp Gy. Cardiovascular Pharmacology '87. Akademiai kiado, 1987: 457-471 (Budapest)
        • Hoffmann W.
        • Förster W.
        Zweijdhresstudie an den Herzinfarkt-Patienten des Bezirkes Cottbus mit 30, 60 und 1000 mg Acetylsalicylsäure (ASS) je Tag — Einfluß auf Reinfarkt-Morbidität und Letalität.
        Z. Klin. Med. 1987; 42: 2097-2101
        • Förster W.
        • Hoffmann W.
        Superior prevention of reinfarction by 30 mg per day aspirin compared with 1000 mg: results of a two years follow-up study in Cottbus.
        in: 2nd ed. Prostaglandins in Clin. Research. Vol. 301. 1989: 187-189
        • WHO
        Evaluation of comprehensive rehabilitation and preventive programmes for patients after acute myocardial infarction.
        in: Report on two working groups. EURO, Copenhagen1973: 8206-8208
        • Hoffmann W.
        • Förster W.
        • Mest H.-J.
        • Taube C.
        • Block H.-U.
        • Braun H.
        Reduced site effects by low dose of acetylsalicylic acid (ASA) in patients with myocardial infarction, estimation of serum thromboxane B2 and PGF2a.
        Biochim. Biomed. Acta. 1984; 43: 467-470
        • Müller R.K.
        Die toxikologisch-chemische Analyse.
        in: Th. Steinkopf-Verlag, Dresden1976: 226
        • Adam J.
        • Enke H.
        Analyse mehrdimensionaler Kontingenztafeln mit Hilfe des Informationsmaßes von Kullback.
        Biom. Z. 1972; : 305-323
        • Reilly J.A.G.
        • FitzGerald G.A.
        Presystemic inhibition of platelet thromboxane formation by simulated, slow release, low dose aspirin in man.
        Clin. Res. 1984; 32: 320A
        • Pedersen A.K.
        • FitzGerald G.A.
        Dose-related kinetics of aspirin, Presystemic acetylation of platelet cyclooxygenase.
        New Engl. J. Med. 1984; 311: 1206-1211
        • Siebert D.J.
        • Bochner F.
        • Imhoff D.M.
        • Watts S.
        • Lloyd J.V.
        • Field J.
        • Bagg B.W.
        Aspirin kinetics and platelet aggregation in man.
        Clin. Pharmacol. Ther. 1983; 33: 367-374
        • Kallman R.
        • Nieuwenhuis H.K.
        • de Groot P.G.
        • van Gijn J
        • Sixma J.J.
        Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PGF1a excretion in healthy subjects.
        Thromb. Res. 1987; 45: 355-361
        • Sinzinger H.
        • O'Grady J.
        • Fitscha P.
        • Kaliman J.
        Extremely low-dose aspirin (one malligram per day) renders human platelets more sensitive to antiaggregation prostaglandins.
        New. Engl. J. Med. 1984; 1052
        • Rasmanis G.
        • Vesterquist O.
        • Green K.
        • Edhag O.
        • Henriksson P.
        Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction.
        Lancet. 1988; 2: 245-247
        • Lorenz R.L.
        • Boehlig B.
        • Uedelhoven W.M.
        • Weber P.C.
        Superior antiplatelet action of alternate day pulsed dosing versus split dose administration of aspirin.
        Am. J. Cardiol. 1989; : 1185-1188
        • Ali M.
        • Zamecnik J.
        • Cerskus A.L.
        • Stoessl A.J.
        • Barnett W.H.
        • McDonald J.W.D.
        Synthesis of thromboxane B2 and prostaglandins by bovine gastric mucosal mikrosomes.
        Prostaglandins. 1977; 14: 819-827
        • Hirsh J.
        • Salzman E.W.
        • Harker L.
        • Fuster V.
        • Dalen J.E.
        • Cairns J.A.
        • Collins R.
        Aspirin and other platelet active drugs, Relationship among dose, effectiveness, and side effects.
        Chest. 1989; 95: 12S-18S
        • Grossman M.I.
        • Matsumoto K.K.
        • Lichter R.J.
        Fecal blood loss produced by oral and intravenous administration of various salicylates.
        Gatroenterology. 1961; 40: 383-388
        • Stampfer M.J.
        • Jakubowski J.A.
        • Deykin D.
        • Schafer A.I.
        • Wilett W.C.
        • Hennekens C.H.
        Effect of alternate-day regular and enteric-coated aspirin on platelet aggregation, bleeding time, and thromboxane A2 levels in bleeding-time blood.
        Am. J. Med. 1986; 81: 400-404
        • Tohgi H.
        • Tamura K.
        • Kimura B.
        • Kimura M.
        • Suzuki H.
        Individual variation in platelet aggregability and serum thromboxane B2 concentrations after low-dose aspirin.
        Stroke. 1988; 19: 700-703
        • Knapp H.R.
        • Healy C.
        • Lawson J.
        • FitzGerald G.A.
        Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men.
        Thromb. Res. 1988; 50: 377-386
        • Young V.P.
        • Giles A.R.
        • Pater J.
        • Corbett W.E.N.
        Sex differences in bleeding time and blood loss in normal subjects following aspirin ingestion.
        Thromb. Res. 1980; 20: 705-709
        • Coppe D.
        • Wessinger S.J.
        • Ransil B.J.
        • Harris W.
        • Salzman E.
        Sex differences in the platelet response to aspirin.
        Thromb. Res. 1981; 23: 1-21
        • Harrison M.J.G.
        • Weisblatt E.
        A sex difference in the effect of aspirin on ‘spontaneous’ platelet aggregation in whole blood.
        Thromb. Haemost. 1983; 50: 773-774
        • Buchanan M.R.
        • Rischke J.A.
        • Butt R.
        • Turpie A.G.G.
        • Rosenfeld J.
        The sex-related difference in the platelet response to aspirin.
        Thromb. Res. 1983; 29: 125-139
        • Elwood P.C.
        ASS und Herzinfarkt Empfehlungen für Klinik und Forschung.
        in: Breddin K. Loew D. Überla K. Dorndorf W. Marx R. Prophylaxe venöser, peripherer, kardialer und zerebraler Gefäßerkrankungen mit Acetylsalicylsäure. F. K. Schattauer Verlag, Stuttgart, New York1981: 107-112
        • Walter E.
        • Breddin K.
        • Lechner K.
        • Loew D.
        • Überla K.
        • Weber E.
        Ergebnisse der Deutsch-Österreichischen Reinfarktstudie und weitere Befunde aus der Heidelberger Patientengruppe.
        in: Breddin K. Loew D. Überla K. Dorndorf W. Marx R. Prophylaxe venöser, peripherer, kardialer und zerebraler Gefäßerkrankungen mit Acetylsalicylsäure. F. K. Schattauer Verlag, Stuttgart, New York1981: 113-123
        • Vane J.R.
        Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs.
        Nature New Biol. 1971; 231: 232-235
        • Siegel M.I.
        • McConnell R.T.
        • Cuatrecasas P.
        Aspirin-like drugs interfere with arachidonic acid metabolism by inhibition of the 12-hydroperoxy-5,8,10,14-eicosatetraenoic acid peroxidase activity of the lipoxygenase pathway.
        in: 2nd ed. Proc. Natl. Acad. Sci, USA. 76. 1979: 3774-3778
        • Eynard A.R.
        • Galli G.
        • Tremoli E.
        • Maderna P.
        • Magni F.
        • Paoletti R.
        Aspirin inhibits platelet 12-hydroxyeicosatetraenoic acid formation.
        J. Lab. Clin. Med. 1986; 107: 73-78
        • Siegel M.I.
        • McConnell R.T.
        • Abrahams S.L.
        • Porter N.A.
        • Cuatrecasas P.
        Regulation of arachidonate metabolism via lipoxygenase and cyclooxygenase by 12-HPETE, the product of human platelet lipoxygenase.
        Biochem. Biophys. Res. Comm. 1979; 89: 1273-1280
        • Violi F.
        • Alessandri C.
        • Pratico D.
        • Guzzo A.
        • Ghiselli A.
        • Balsano F.
        Inhibition of cyclooxygenase-independent platelet aggregation by sodium salicylate.
        Thromb. Res. 1989; 54: 583-593
        • Cerletti C.
        • Carriero M.R.
        • de Gaetano G.
        Platelet-aggregation response to single or paired aggregating stimuli after low-dose aspirin.
        New Engl. J. Med. 1986; 314: 316-318
        • White H.L.
        • Faison L.D.
        Inhibition of lyso-PAF: Acetyl-CoA acetyltransferase by salicylates and other compounds.
        Prostaglandins. 1988; 35: 939-944
        • Denburg J.A.
        • Williams D.B.
        • Kinlough-Rathbone R.L.
        • Cazenave J.P.
        • Bienenstock J.
        Platelet activating factor: regulation by mast cells and aspirin.
        Agents and Actions. 1984; 14: 300-305
        • Lauri D.
        • Cerletti C.
        • de Gaetano G.
        Contribution of ADP to the amplification of primary platelet aggregation by platelet activating factor (PAF): modulatory role of aspirin.
        Agents and Actions. 1985; 17: 506-511
        • Lecrubier C.
        • Conard J.
        • Horellou M.H.
        • Samama M.
        Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin.
        Agents and Actions. 1983; 13: 77-80
        • Bomalaski J.S.
        • Alvarez J.
        • Touchstone J.
        • Zurier R.B.
        Alterations of uptake and distribution of eicosanoid precursor fatty acids by aspirin.
        Biochem. Pharmacol. 1987; 36: 3249-3253
        • Levin R.I.
        • Harpel P.C.
        • Weil D.
        • Tsun-San Chang
        • Rifkin D.B.
        Aspirin inhibits vascular plasminogen activator activity in vivo.
        J. Clin. Invest. 1984; 74: 571-580
        • Moroz L.A.
        Increased blood fibrinolytic activity after aspirin ingestion.
        N. Engl. J. Med. 1977; 296: 525-529
        • Meyer O.O.
        • Howard B.B.
        Production of hypoprothrombinaemia and hypocoagulability of blood with salicylates.
        in: 2nd ed. Proc. exp. Med.53. 1943: 234-237
        • Roncaglioni M.C.
        • Ulrich M.M.W.
        • Müller A.D.
        • Soute B.A.M.
        • de Boor M.A.D.
        • van den Berg C.
        • Vermeer C.
        The vitamin-K antagonism of salicylate and warfarin.
        Thromb. Res. 1986; 42: 727-736
        • Shapiro S.
        • Redish M.H.
        • Campbell H.A.
        Studies of prothrombin iv: prothrombinopenic effect of salicylate in man.
        in: 2nd ed. Proc. Soc. exp. Med.53. 1943: 251-254

      Article info

      Publication history

      Accepted: April 25, 1991
      Received: December 24, 1990

      Identification

      DOI: https://doi.org/10.1016/0952-3278(91)90051-6

      Copyright

      © 1991 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX